|
Pharmaleads Technology Platform is based on :
A solid proven base in medicinal chemistry with patented chemical families,
Patented enzymes substrates libraries,
A proprietary technology (Fluofast®) allowing both proteinases (all classes) and corresponding substrates identification,
An innovative technology extended to identification of substrates for phosphatases and kinases,
A downstream approach towards pharmaceutical applications in the field of analgesia.
Such technology allows also an upstream approach to identify new pharmaceutical targets and innovative drug as Zinc metallopeptidases inhibitors whose pharmacological potential is high. Pharmaleads strategy will result in continuously fuelling clinical development programs with innovative high interest in new chemical entities (NCE), addressing pathologies that are major health concerns in valuable worldwide long term markets.
|
